New product release

VaxiraVaxira ®, Is a new immuno-therapeutic agent or therapeutic vaccine whose active ingredient is the anti-idiotype monoclonal antibody Racotumomab adsorbed in aluminum hydroxide as adjuvant.
This product showed great benefits in the treatment of lung cancer small cell.

view more

News

view all

2014.04.23

New partner in Turkey

Hasbiotech is Recombio´s exclusive partner in Turkey.

view more

2013.06.04

ASCO 2013

Racotumomab was safeand showed a promising survival improvement in advanced NSCLC patients in progression after first line onco-specific treatment (presented at ASCO 2013).

view more

Products

view all

Racotumomab (1E10) anti-idiotype antibody

RECOMBIO is working on two different vaccines for the treatment of cancer; one is a monoclonal Racotumomab (1E10) anti-idiotype antibody and the other one is based on nominal antigen NGcGM3.

view more